Iovance Biotherapeutics (IOVA) Aktievy
Iovance Biotherapeutics, Inc, ett biofarmaceutiskt företag i kommersiell fas, utvecklar och kommersialiserar cellterapier med autologa tumörinfiltrerande lymfocyter för behandling av metastaserande melanom och andra solida tumörformer i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
IOVA Community Fair Values
Create NarrativeSee what 149 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$18
FV
76.5% undervärderad intrinsisk rabatt516
users have viewed this narrative4users have liked this narrative
2users have commented on this narrative
7users have followed this narrative
Iovance Biotherapeutics, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$4.23 |
| 52 veckors högsta | US$5.63 |
| 52 veckors lägsta | US$1.70 |
| Beta | 0.69 |
| 1 månads förändring | 11.90% |
| 3 månaders förändring | 14.32% |
| 1 års förändring | 126.20% |
| 3 års förändring | -45.49% |
| 5 års förändring | -81.19% |
| Förändring sedan börsintroduktionen | -18.78% |
Senaste nyheter och uppdateringar
Ny berättelse • Jul 03
Why I think Iovance is undervalued
In my opinion, Iovance is one of those biotech companies where the market is still focused on what went wrong in the past instead of what could happen over the next few years. After a disappointing commercial launch in 2025, many investors lost confidence and the share price fell sharply.
Uppdatering av berättelse • Jun 17
IOVA: Replimune Setback And IL 12 TIL Trial Will Support Higher P/E
The analyst price target for Iovance Biotherapeutics has been trimmed by $2 as analysts factor in updated competitive expectations following recent developments at Replimune while still reflecting broadly consistent fair value and growth assumptions. Analyst Commentary Recent research on Iovance Biotherapeutics centers on how competitive developments and regulatory news in skin cancer treatments may influence sentiment on the stock.Seeking Alpha • Jun 17
Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds
Summary IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA’s development path. IOVA guides for its current cash to last into early 2028, although the company could continue to raise further funds using its at-the-market facility. Read the full article on Seeking AlphaRecent updates
Ny berättelse • Jul 03
Why I think Iovance is undervalued
In my opinion, Iovance is one of those biotech companies where the market is still focused on what went wrong in the past instead of what could happen over the next few years. After a disappointing commercial launch in 2025, many investors lost confidence and the share price fell sharply.Uppdatering av berättelse • Jun 17
IOVA: Replimune Setback And IL 12 TIL Trial Will Support Higher P/E
The analyst price target for Iovance Biotherapeutics has been trimmed by $2 as analysts factor in updated competitive expectations following recent developments at Replimune while still reflecting broadly consistent fair value and growth assumptions. Analyst Commentary Recent research on Iovance Biotherapeutics centers on how competitive developments and regulatory news in skin cancer treatments may influence sentiment on the stock.Seeking Alpha • Jun 17
Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds
Summary IOVA guides for $350M–$370M 2026 revenue (36% YoY growth), with Q2'26 expected to be a record Amtagvi quarter. Expansion into new indications (NSCLC, endometrial, sarcoma) and global markets underpins the pipeline-in-a-drug thesis. A more receptive FDA increases the likelihood of accelerated approvals based on single-arm data, streamlining IOVA’s development path. IOVA guides for its current cash to last into early 2028, although the company could continue to raise further funds using its at-the-market facility. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 03
IOVA: Competitive Setbacks And New IL 12 Program Will Support Higher Future P/E
Analysts have modestly adjusted their outlook on Iovance Biotherapeutics, with recent price target changes including UBS moving to $4 from $2 and Chardan trimming its target by $2. These revisions reflect mixed views on fundamentals, the pace of Amtagvi uptake, and potential benefits from a competing product setback.Uppdatering av berättelse • May 14
IOVA: Margin Gains And 2026 Sarcoma Readouts Will Support Higher Future P/E
Analysts have trimmed the fair value estimate for Iovance Biotherapeutics to $14.00 from $16.00, reflecting updated views on revenue growth potential, margin trajectory, and a higher future P/E multiple, following recent research highlighting both Q4 operational progress and ongoing uncertainties around Amtagvi acceleration. Analyst Commentary Recent Street research shows a mixed but generally constructive tone around Iovance Biotherapeutics, with several bullish analysts highlighting improving execution in Q4, progress on margins, and potential benefits from external events in the competitive set.Analysartikel • May 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) missed earnings with its latest first-quarter results, disappointing...
Uppdatering av berättelse • Apr 29
IOVA: Q4 Margin Progress And Sarcoma Data Will Drive Upside Potential
Narrative Update: Iovance Biotherapeutics The analyst price target for Iovance Biotherapeutics has been lifted to $4. This reflects updated models that incorporate Q4 fundamentals, margin progress and expectations around Amtagvi and broader trial momentum, while still acknowledging areas of uncertainty highlighted by recent Street research.Uppdatering av berättelse • Apr 14
IOVA: Q4 Margin Gains And Sarcoma Data Are Expected To Drive Upside
The average analyst price target for Iovance Biotherapeutics has moved higher toward $4, supported by research citing improved Q4 fundamentals, margin progress, and early signs that initial launch issues may be easing. Analyst Commentary Recent research highlights a mix of optimism around product execution and margins alongside pockets of caution on valuation and growth risks.Uppdatering av berättelse • Mar 31
IOVA: Margin Progress And 2026 Sarcoma Data Outlook Will Support Higher Future P/E
The analyst fair value estimate for Iovance Biotherapeutics has been adjusted from $17.00 to $16.00, reflecting updated views on revenue growth, margins, and future P/E assumptions as analysts respond to recent price target moves and Q4 results across the Street. Analyst Commentary Street research around the latest quarter points to a generally constructive shift in sentiment, with several bullish analysts lifting price targets and, in one case, upgrading the rating on Iovance Biotherapeutics.Uppdatering av berättelse • Mar 16
IOVA: Fair Outlook Balances Q4 Progress With 2026 Clinical And Launch Risks
The analyst price target for Iovance Biotherapeutics has shifted from $2 to $4 as analysts point to stronger Q4 fundamentals, improving margins, ongoing manufacturing progress, and early signs that some initial launch issues for Amtagvi may be easing, even while longer term revenue acceleration remains uncertain. Analyst Commentary Recent Street research around Iovance Biotherapeutics reflects a mixed setup, with price target changes clustered across a wide range and ratings spanning Neutral to Buy.Uppdatering av berättelse • Mar 02
IOVA: Elevated Future P/E Will Likely Clash With 2026 Clinical Data Risks
Analysts have lifted their price targets on Iovance Biotherapeutics from a range starting at $3 to as high as $16, citing Q4 revenue momentum, improving gross margins and manufacturing efficiency, and expectations for more clinical data in 2026. Analyst Commentary Recent research highlights a split in how Wall Street views Iovance Biotherapeutics, with some firms lifting price targets on the back of Q4 execution and others trimming expectations while still acknowledging operational progress.Uppdatering av berättelse • Feb 16
IOVA: Elevated Future P/E Will Likely Expose Execution Risk
Analysts have raised their price target on Iovance Biotherapeutics by $0.50, citing updated assumptions around fair value, growth, margins, and future P/E that reflect recent Street research. Analyst Commentary Recent Street research on Iovance Biotherapeutics has highlighted a mix of optimism and caution around the updated price target, with some readers likely to focus less on the small US$0.50 change and more on what it implies about risk and execution.Uppdatering av berättelse • Feb 02
IOVA: Reaffirmed 2025 Revenue Outlook Will Support A Higher Future P/E
Analysts have trimmed their fair value estimate for Iovance Biotherapeutics from US$20.00 to US$17.00, citing updated assumptions that include a slightly higher discount rate, a lower projected revenue growth rate, a modestly higher profit margin, and a reduced future P/E multiple. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the expected range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Key Developments).
Uppdatering av berättelse • Jan 19
IOVA: Lung Cancer Trial Progress Will Drive Bullish Repricing Ahead
Analysts have kept their price target for Iovance Biotherapeutics steady at US$8.35, citing only minor tweaks to inputs such as the discount rate and long term P/E assumptions rather than any fundamental shift in their outlook. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, keeping the range at US$250 million to US$300 million for the first full calendar year of Amtagvi sales (Company guidance).Uppdatering av berättelse • Jan 05
IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly increased their price target on Iovance Biotherapeutics by 0.10 dollars to reflect slightly lower perceived risk, as seen in a reduced discount rate, while maintaining robust long term revenue growth and profit margin expectations alongside a marginally higher future price to earnings multiple. What's in the News Iovance reaffirmed its full year 2025 revenue guidance of 250 to 300 million dollars for the first full calendar year of Amtagvi sales, signaling confidence in launch momentum (company guidance) Interim data from the registrational Phase 2 IOV-LUN-202 trial showed a 25.6 percent objective response rate for lifileucel monotherapy in previously treated advanced nonsquamous NSCLC without actionable mutations, including 2 complete and 7 partial responses and a 71.8 percent disease control rate (company trial update) The median duration of response for lifileucel in IOV-LUN-202 has not yet been reached after a median follow up of 25.4 months, indicating durable benefit among responding NSCLC patients (company trial update) Valuation Changes Fair Value: increased slightly from 8.25 dollars to 8.35 dollars, reflecting a modest uplift in the intrinsic valuation estimate.Uppdatering av berättelse • Dec 15
IOVA: Future Lung Cancer Data Will Drive Renewed Bullish Momentum
Analysts have modestly reduced their price target on Iovance Biotherapeutics to reflect slightly slower projected revenue growth, a meaningfully lower long term profit margin outlook, and a higher assumed future price to earnings multiple, while leaving the estimated fair value effectively unchanged at about 8.25 dollars per share. What's in the News Iovance Biotherapeutics reaffirmed its full year 2025 revenue guidance, targeting between 250 million dollars and 300 million dollars in the first full calendar year of Amtagvi sales (company guidance).Uppdatering av berättelse • Nov 30
IOVA: Future Phase 2 Data Will Drive Renewed Bullish Momentum
Analysts have raised their price target for Iovance Biotherapeutics from $7.75 to $8.25 per share, citing updated financial metrics and modestly adjusted long-term growth assumptions. What's in the News Iovance Biotherapeutics reaffirmed its revenue guidance for the full year 2025, projecting $250 to $300 million in the first full calendar year of Amtagvi sales.Uppdatering av berättelse • Nov 16
IOVA: Future Profitability Outlook Will Drive Renewed Investor Interest
Analysts have adjusted their price target for Iovance Biotherapeutics from $8.00 to $7.75. This change reflects updated views on the company's growth trajectory and profitability outlook.Analysartikel • Nov 08
Here's What Analysts Are Forecasting For Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) After Its Third-Quarter Results
Shareholders of Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) will be pleased this week, given that the stock price is...Uppdatering av berättelse • Nov 02
IOVA: Advanced Melanoma Approval and Equity Raise Will Drive Upside Potential
Analysts have lowered their price target for Iovance Biotherapeutics from $9.10 to $8.00. They cite updated expectations for slower revenue growth, compressed profit margins, and a higher required rate of return.Uppdatering av berättelse • Aug 25
Oncology Expansion And Global Approvals Will Unlock Future Markets
The consensus analyst price target for Iovance Biotherapeutics has been revised downward to $9.10 as slower-than-expected Amtagvi commercial adoption and logistical challenges outweigh positive early clinical response data. Analyst Commentary Bearish analysts cite a slower-than-expected commercial launch for Amtagvi in second-line melanoma, driving down sentiment and price targets.Uppdatering av berättelse • Aug 10
Oncology Expansion And Global Approvals Will Unlock Future Markets
The decrease in Iovance Biotherapeutics' consensus price target is primarily driven by a reduction in expected annual revenue growth from 49.7% to 45.5%, resulting in a lowered fair value estimate from $10.00 to $9.10. What's in the News Five-year results from the Phase 2 C-144-01 trial showed Amtagvi (lifileucel) produced a median OS of 13.9 months and a 31.4% objective response rate in advanced melanoma patients; 19.7% survived at five years with durable responses and no new safety concerns.Analysartikel • Jul 22
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Fly 26% But Investors Aren't Buying For Growth
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shareholders are no doubt pleased to see that the share price has bounced...Analysartikel • May 16
Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) 46% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) share price has dived 46% in the...Analysartikel • May 13
News Flash: 12 Analysts Think Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Earnings Are Under Threat
The analysts covering Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) delivered a dose of negativity to shareholders...
Ny berättelse • Apr 22
US Launch And Global Expansion Will Create New Opportunities
The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share.Seeking Alpha • Apr 22
Iovance Biotherapeutics: Only For The Brave
Summary Shares of Iovance Biotherapeutics have plummeted post-Amtagvi approval due to excessive ATM usage and 7% shareholder dilution, despite solid financials and reaffirmed FY25 outlook. Iovance's TIL therapy, Amtagvi, is FDA-approved for advanced melanoma and is in trials for other oncology indications, including NSCLC and endometrial cancer. Despite significant cash burn and unprofitability until at least FY27, Iovance's extensive trials and potential blockbuster status for Amtagvi present multi-bagger potential. An analysis around Iovance Biotherapeutics follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Mar 18
Iovance: The Company Makes It Hard To Estimate Revenue Growth
Summary Iovance reported Q4'24 revenues of $25M from Proleukin, a 51% increase from the prior quarter, but Amtagvi revenues of 48.7M, were up just 16% from the prior quarter. Proleukin revenues could be a leading indicator for Amtagvi revenues, but the company also supplied a new distributor in Q4'24, making it hard to judge Q1'25 Amtagvi growth. Obsidian Therapeutics represents a relevant competitor with a cell therapy called OBX-115, that has potential advantages over lifileucel, although IOVA has its own next-gen therapies in development. Read the full article on Seeking AlphaAnalysartikel • Mar 02
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported Earnings, And Analysts Cut Their Target Price
There's been a major selloff in Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares in the week since it released its...Seeking Alpha • Feb 28
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Summary Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances showed mixed results, with $42.1M and $48.7M in Amtagvi revenues, respectively, and a notable cash burn. Despite high costs and competition, Amtagvi remains a preferred option in PD-1-refractory melanoma, with plans to increase its price for better margins. Given the complex and costly nature of TIL therapy, I downgrade IOVA stock to “hold,” acknowledging both its potential and significant risks. Read the full article on Seeking AlphaAnalysartikel • Jan 11
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) shares are down a considerable 25...Seeking Alpha • Dec 17
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't
Summary Iovance's guidance for FY2025 is for total product revenues of $450M-$475M, reflecting confidence in Amtagvi's strong market launch. Preliminary Q4'24 numbers on patient infusions could be considered to reflect a slowing rate of growth, albeit still growth, or just some seasonality, among other possibilities. IOVA can nonetheless meet its FY2025 guidance, although timely approval ex-US of Amtagvi will likely be required, with UK approval in H1'25 and EU approval in H2'25 possible. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
Summary Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors. The company is progressing towards profitability, with promising pipeline developments and potential 25-40% IOVA stock price growth over the next 12 months. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
Iovance Biotherapeutics: Moving To The Next Phase
Summary Iovance Biotherapeutics' Amtagvi has gained rapid market traction post-FDA approval, with strong Q3 performance and promising revenue projections for 2024 and beyond. The company's growth prospects are bolstered by potential regulatory approvals in international markets and ongoing trials in other cancer types, including NSCLC. Despite the positive outlook, risks include market penetration challenges, regulatory hurdles, competition, and financial sustainability concerns due to ongoing cash burn. I am looking to add to my IOVA position at current valuations, anticipating a potential reversal and long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Sep 06
Iovance Therapeutics: Historic Product, Tough Commercial Outlook
Summary Iovance's cell therapy Amtagvi has received an historic FDA approval for treating unresectable or metastatic melanoma, but its stock has fallen over 70% since 2020. Despite first revenues from Amtagvi and Proleukin in Q2, financial uncertainties and a high cash burn raise concerns about Iovance's long-term profitability and market viability. Management's lack of detailed revenue breakdown and challenges with insurance approvals and competition create a little uncertainty around Amtagvi's commercial success. While promising label expansions and full approval could boost prospects, current financial, regulatory, and commercial uncertainties justify maintaining a "Hold" rating. Read the full article on Seeking AlphaAnalysartikel • Aug 11
Earnings Update: Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Just Reported And Analysts Are Boosting Their Estimates
Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) just released its quarterly report and things are looking bullish...Seeking Alpha • Aug 11
Iovance's Tumor-Fighting TILs Are Just Warming Up (Rating Upgrade)
Summary Iovance's Q2 2024 revenue of $31.1 million surpassed analyst expectations. Amtagvi, Iovance's TIL therapy, generated $12.8 million in its first full quarter post-approval. Iovance's ongoing trials in NSCLC and endometrial cancer could expand lifileucel's market potential. The company projects $160–$165 million in full-year 2024 revenue, with substantial growth expected by 2025. I am upgrading Iovance stock to a "buy" based on the improved outlook for Amtagvi and potential revenue growth. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Iovance Biotherapeutics: Amtagvi Launch Continues Upward
Summary The Amtagvi launch has seen over 100 patients enrolled for therapy since approval, with potential for Q2'24 earnings to reflect some initial sales. IOVA's enrollment of the TILVANCE-301 continues, with updates on enrollment serving as a potential catalyst. Key cohorts of a study of lifileucel in non-small cell lung cancer are set to complete enrollment in 2025. Read the full article on Seeking AlphaSeeking Alpha • May 10
Iovance Q1 Earnings Review: Not Enough Data To Draw Conclusions On Amtagvi
Summary Iovance Biotherapeutics reported its Q1 2024 earnings yesterday. The company made a net loss of $(113m), or $(0.42) per share. Iovance secured a historic approval for a first solid tumor targeting cell therapy in mid-Feb, triggering overnight gains of close to 100%. Now, the market is turning its attention to revenue figures and patient enrollment for Amtagvi, approved to treat melanoma. Yesterday's updates provided by management seemed upbeat, but analysts had many questions and the share price has been falling today. In this post, I provide a thorough overview of the state of play post Q1 '24 earnings, and speculate on key themes that will dictate IOVA stock price movements going forward. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
Summary Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production capacity and aims to become a global leader in TIL therapies for cancer patients. Insider ownership has increased by over 50%, indicating strong confidence in the company's future results. Read the full article on Seeking AlphaSeeking Alpha • Mar 25
Iovance Biotherapeutics: Initial Amtagvi Launch In Focus
Summary Iovance's tumor-infiltrating lymphocyte (TIL) product, Amtagvi, was recently approved by the FDA for the treatment of advanced melanoma patients who have failed a PD-1 blocking antibody. Initial numbers from the early days of the launch can be considered when trying to project revenues from Amtagvi going forward. IOVA can improve potential revenues by gaining approval of its TIL therapies like Amtagvi outside of the US and in new indications. In the short term, however, the focus may be on the current Amtagvi launch, where some success may already be reflected in the price. Read the full article on Seeking AlphaSeeking Alpha • Feb 20
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
Summary Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma. The FDA has granted approval for Iovance's TIL therapy, named Amtagvi, for the treatment of advanced melanoma after anti-PD-1 and targeted therapy. Amtagvi has the potential to carve out a niche in the crowded melanoma treatment market, offering hope to patients with few options left. Read the full article on Seeking AlphaSeeking Alpha • Jan 19
Iovance Biotherapeutics: Preparing For Volatility Around Lifileucel's Upcoming PDUFA Date
Summary Iovance Biotherapeutics is preparing for the extended FDA deadline to determine the approval of lifileucel for advanced melanoma treatment. The FDA has put a clinical hold on the company's Phase II study for LN-145, which has raised concerns about the approval of lifileucel. Iovance has the capacity and preparations for a successful launch of lifileucel in the US, with plans for a potential approval in Europe. Read the full article on Seeking AlphaAktieägarnas avkastning
| IOVA | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | -1.9% | -2.4% | 0.7% |
| 1Y | 126.2% | 35.9% | 20.6% |
Avkastning vs industri: IOVA översteg US Biotechs branschen som gav 35.9 % under det senaste året.
Avkastning vs Marknaden: IOVA översteg US marknaden som gav 20.6 % under det senaste året.
Prisvolatilitet
| IOVA volatility | |
|---|---|
| IOVA Average Weekly Movement | 11.0% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: IOVA har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IOVA s veckovolatilitet ( 11% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2007 | 975 | Frederick Vogt | www.iovance.com |
Iovance Biotherapeutics, Inc. är ett kommersiellt biofarmaceutiskt företag som utvecklar och kommersialiserar cellterapier med autologa tumörinfiltrerande lymfocyter för behandling av metastaserande melanom och andra solida tumörformer i USA och internationellt. Företaget erbjuder Amtagvi, en individualiserad T-cellsterapi för cancer i solida tumörer och för behandling av vuxna patienter med tidigare behandlad avancerad, inoperabel eller metastaserande melanom; och Proleukin, en interleukin-2-produkt för behandling av patienter med metastaserande melanom och metastaserande njurcancer. Företaget utvecklar också lifileucel för behandling av melanom, livmoderhalscancer, icke-småcellig lungcancer (NSCLC), endometriecancer samt skivepitelcancer i huvud och hals (HNSCC); LN-145-S1 för behandling av melanom och HNSCC; LN-145 Gen 3 och kärnbiopsi för behandling av NSCLC; LN-145 Gen 3 för behandling av melanom och HNSCC; IOV-2001 för behandling av kronisk lymfatisk leukemi och småcellig lymfatiskt lymfom; IOV-4001 för behandling av melanom och NSCLC; och IOV-3001 för användning i behandlingsregimen för TIL-terapi.
Iovance Biotherapeutics, Inc. Sammanfattning av grunderna
| IOVA grundläggande statistik | |
|---|---|
| Börsvärde | US$1.95b |
| Vinst(TTM) | -US$353.86m |
| Intäkter(TTM) | US$285.61m |
6.6x
P/S-förhållande-5.3x
P/E-förhållandeÄr IOVA övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IOVA resultaträkning (TTM) | |
|---|---|
| Intäkter | US$285.61m |
| Kostnad för intäkter | US$172.97m |
| Bruttovinst | US$112.64m |
| Övriga kostnader | US$466.50m |
| Intäkter | -US$353.86m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.79 |
| Bruttomarginal | 39.44% |
| Nettovinstmarginal | -123.90% |
| Skuld/egenkapitalförhållande | 0.1% |
Hur har IOVA utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 21:34 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Iovance Biotherapeutics, Inc. bevakas av 20 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Colleen Kusy | Baird |
| Madhu Kumar | Baird |
| Peter Lawson | Barclays |